Classification Codes), and Disease Count (identified using ICD9 codes). Baseline model included age, gender and race. Weighted linear regression analyses were used to risk-adjust PCS and MCS. Model performance was evaluated using adjusted-R squares. RESULTS: According to the MEPS, there were 20.9 million diabetic patients (unweighted sample 2155) in 2008 with mean age 59.4 (Ϯ14.2) years. The mean (Ϯ SD) PCS and MCS scores for diabetes patients were 40.51 (Ϯ0.37) and 48.94 (Ϯ0.34) 
OBJECTIVES:
Health economic modelling has paid limited attention to incorporating the effects patients' psychological characteristics can have on the effectiveness of a treatment. The objective of this study was to test the feasibility of incorporating psychological prediction models of treatment response within an economic model of a diabetes structured education programme: Dose Adjustment For Normal Eating (DAFNE). METHODS: Data from the National Institute for Health Research DAFNE Research Programme were used to support all analyses. Three regression models were used to investigate the relationships between patients' baseline psychological characteristics and their 12-month HbA1 c response to DAFNE. The regression models were integrated with a patient-level simulation model of type 1 diabetes to evaluate the cost-effectiveness of two new policies (providing DAFNE only to predicted responders and offering a follow-up intervention to predicted non-responders) compared with current practice. The model estimated costs and quality-adjusted life-years over a 50-year time horizon from a UK National Health Service perspective. Deterministic sensitivity analyses were conducted. RESULTS: Psychological predictors of treatment response were successfully integrated with the health economic simulation model and allowed new treatment policies to be evaluated. The results suggest that providing DAFNE only to predicted responders is dominated by current practice (incremental costs ranged from £297 to £616 and incremental QALYs from -0.112 to -0.209). This result was insensitive to the psychological prediction model used and to the majority of sensitivity analysis assumptions tested. The results suggest that providing a follow-up intervention to predicted non-responders dominates current practice. This result was sensitive to model assumptions. CONCLUSIONS: By collecting data on psychological variables for a subgroup of patients before an intervention, we can construct predictive models of treatment response to behavioural interventions and incorporate these into health economic simulation models to investigate more complex treatment policies. Further research using this methodology is indicated.
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PIH1 THE CLINICAL CONSEQUENCES OF EXPOSURE TO CLINICALLY IMPORTANT DRUG-DRUG INTERACTIONS
Malone DC, Hines LE, Brown S University of Arizona, Tucson, AZ, USA OBJECTIVES: To evaluate the clinical and economic consequences of exposure to potential drug-drug interactions (PDDIs). METHODS: This study was a case-control study conducted using MarketScan data from 2004 to 2008. A total of 20 PDDIs were evaluated. Eligible persons were required to have a new object drug (medication affected by the interaction claim. For each person the presence of a PDDI (case) was ascertained using first and last dates of object drug usage overlapped with those dates for the precipitant drug (medicaition causing the interation). The follow-up period was 30 days for all PDDIs and 60 days for amiodarone. For each PDDI, cases were matched one-to-one to controls using unconditional logistic regression with three variables: age, gender and Charlson score. Matches occurred where the difference in propensity scores between a case and control was between 0.0001 and 0.01. Medical outcomes were PDDI-pair specific based on a priori defined health outcomes (using ICD9 codes) occurring during the follow-up period. Logistic and GLM regression models were constructed to evaluate the presence of negative medical outcomes and costs, respectively. RESULTS: The total number of case/ control pairs per PDDI of interest ranged from 570 for digoxin/azole antifungals to 128,423 for warfarin/statins. For negative health events, non-significant findings occurred for only three PDDIs. Among the 17 PDDIs with significant findings, odds ratios for negative outcomes ranged from 1.67 (95%CI:1.39-2.02) for warfarin/fibrates to 12.50 (95%CI:2.96-52.77) for digoxin/macrolide antibiotics. With respect to total health care costs, higher expenditures occurred among persons with a PDDI than controls for all 20 PDDIs examined (pϽ 0.001). Cost differences ranged from $554 for warfin/fibrates to $8814 for digoxin/azole antifungals. CONCLUSIONS: Persons exposed to PDDIs were more likely to experience negative health outcomes and have higher costs as compared to propensity-score matched controls. PDDIs are associated with significant morbidity and expense. 
PIH2 RELATIONSHIP BETWEEN MUSCLE MASS AND MUSCLE STRENGTH IN THE ELDERLY POPULATION IN THE UNITED STATES
OBJECTIVES:
To characterize the relationship between muscle mass and muscle strength in the US elderly population, and examine potential sources of population heterogeneity. METHODS: This study included individuals aged 50 and above from the National Health and Nutrition Examination Survey (NHANES) 1999-2004 databases. Distributions of muscle mass measured via the height-adjusted appendicular skeleton muscle mass (aASM, in kg/m2), and muscle strength via the isokinetic quadriceps strength (IQS, in Newtons) were examined, stratified by age and gender. The relationship between muscle mass (aASM) and muscle strength (IQS) was summarized using the partial correlation coefficient adjusting for age and gender. The effects of individual comorbid medical conditions and body mass index (BMI) on the relationship between muscle mass and muscle strength were assessed using a series of multivariable regression models, using survey strata and weighting, with aASM, age, gender, and each variable of interest (e.g., diabetes) predicting muscle strength; and with an interaction between aASM and the variable of interest included to assess for effect modification. RESULTS: The study included 5139 individuals with a mean age of 66.2 years and 50.2% female. Mean (SE) aASM was 7.2 (0.03) and declined with age, from 7.6 (0.05) for 50-54 year olds to 6.4 (0.04) for those 80 and older. Mean (SE) IQS was 362.3 (2.8), declining from 426.6 (6.7) for 50-54 year olds to 241.6 (6.5) for those 80 and older. aASM and IQS were positively correlated (partial correlation coefficientϭ0.365, pϽ0.0001). Interactions between ASM and several factors (e.g., diabetes, arthritis and BMI) were statistically significant (PϽ0.05). CONCLUSIONS: Among individuals aged 50 and above in the United States, muscle mass and muscle strength are positively correlated. BMI and certain comorbid medical conditions (e.g., diabetes and arthritis) appear to modify the effect of muscle mass on muscle strength. 
PIH3 USE OF MIXED TREATMENT COMPARISON METHODS IN ESTIMATING EFFICACY OF TREATMENTS FOR HEAVY MENSTRUAL BLEEDING
OBJECTIVES:
For use in a cost-effectiveness model, synthesize available data to derive estimates of efficacy for several classes of treatments for heavy menstrual bleeding (HMB). METHODS: A systematic review identified randomized controlled trials that reported data on menstrual blood loss (MBL) at baseline and one or more follow-up times. The primary measure of efficacy was the proportion of women who achieved MBL Ͻ80mL per cycle (month), as measured by the alkaline hematin method. Complicating the analysis, some trials reported various summary statistics for MBL, and others used scores from pictorial blood-loss assessment charts (PBAC). Estimation of the primary measure from those diverse data took advantage of the approximately lognormal distributions of MBL and PBAC scores. Also, reported follow-up times varied substantially. Estimates of efficacy by treatment class and time were obtained from a Bayesian mixed treatment comparison (MTC) model. The model also included effects for treatment class, study, and the combination of treatment class and study and an adjustment for baseline mean MBL.
RESULTS:
The evidence network comprised eight treatment classes and 34 ran-
domized clinical trials (RCTs), with follow-up times from 1 to 36 months. Efficacy at three months of follow-up (estimated as the posterior median) ranged from 87.5% for the levonorgestrel-releasing intrauterine system (LNG-IUS) to 14.2% for progestogens administered for less than two weeks out of four in the menstrual cycle. The 95% credible intervals for most estimates were quite wide, mainly because of the limited evidence for many combinations of treatment class and follow-up time and the uncertainty from estimating %MBLϽ80mL from other outcome data. CONCLUSIONS: LNG-IUS and endometrial ablation have high efficacy for HMB. The study yielded useful insights on MTC in sparse evidence networks. Diversity of outcome measures and follow-up times in the HMB literature presented considerable challenges. The Bayesian credible intervals reflected the various sources of uncertainty.
PIH4 IS SILDENAFIL -APOMORPHINE SUBLINGUAL COMBINATION SIGNIFICANTLY MORE EFFECTIVE THAN SUBLINGUAL SILDENAFIL IN TREATING ERECTILE DYSFUNCTION?
Solayman 
OBJECTIVES:
To test the efficacy of a sildenafil (50 mg) and apomorphine (3 mg) sublingual combination in treating male Erectile Dysfunction (ED) in comparison to sublingual sildenafil (50 mg) that shows an increasing number of non-responders. METHODS: In all, 50 eligible ED patients were enrolled into a prospective singleblinded crossover study with two treatment periods, each of 4 weeks, separated by a 2-week washout period. A randomization list in blocks in closed packets was used to randomize the patients to receive sildenafil then the combination or the combination then sildenafil. The primary efficacy endpoint was the percent of attempts resulting in erection firm enough for intercourse. Other efficacy endpoints included the percent of attempts resulting in successful intercourse, change in the score of the 5-item version of the International Index of Erectile Function (IIEF-5) from baseline, response to Sexual Encounter Profile (SEP) diary questions 2 and 3, and patient's preference (Of the two study interventions, which one did you prefer?). RESULTS: Only 43 patients completed the whole schedule and had results evaluable for efficacy. Sildenafil -apomorphine combination had a significantly higher estimate than sildenafil in regard to the mean percent of attempts resulting in erection firm enough for intercourse (77.6% vs. 63.1%, p Ͻ0.001) and resulting in successful intercourse (51.1% vs. 34%, p Ͻ0.001), as well as erectile function as evaluated by the change in the median IIEF-5 score from baseline (18 vs. 15 with baseline of 7, PϽ0.001). Also, the proportion of affirmative answers regarding the SEP diary was significantly higher after the combination (question 2: 79.1% vs. 55.8% PϽ0.01 and question 3: 65.1% vs. 44.2%, PϽ0.05). At the end of the study, patient preference was 88.4% for the combination and 4.6% for sildenafil. CONCLUSIONS: Sildenafil -apomorphine sublingual combination was significantly more effective than sublingual sildenafil in treating ED. 
PIH5 SYSTEMATIC REVIEW COMPARING THE EFFICACY OF THE 5-ALPHA REDUCTASE INHIBITORS (5-ARIS) DUTASTERIDE AND FINASTERIDE IN THE TREATMENT OF BENIGN PROSTATIC HYPERPLASIA (BPH)
Conte
OBJECTIVES:
Benign prostatic hyperplasia (BPH) is a chronic, progressive disease with important healthcare and economic implications. 5-alpha reductase inhibitors (5-ARIs), dutasteride and finasteride are effective treatments. If untreated, BPH may lead to complications such as acute urinary retention (AUR) and the need for surgery (NfS). The aim of this review is to compare the efficacy of dutasteride and finasteride in reducing episodes of AUR and the NfS related to BPH. METHODS: MEDLINE, Lilacs and the Cochrane Central Register of Controlled Trials were searched (from inception to September 2011) to retrieve randomized clinical trials (RCTs) and observational studies evaluating these drugs. The search included articles published in English, Portuguese, and Spanish. Patients with confirmed diagnosis of BPH were included. We analyzed data from studies that reported the number of AUR or NfS following treatment with dutasteride or finasteride. RESULTS: The literature search identified 24 potential full-text publications; 9 RCTs (where 9 were duplicates) and 6 observational/ retrospective studies. No RCT headto-head comparison was found. Indirect efficacy comparison between the two 5-ARIs, based on RCTs, was deemed inappropriate due to the heterogeneity of the patients included in the trials, differences in outcome measurements, study design and combination therapies (i.e., alpha blockers) used in the studies. Direct comparison of dutasteride and finasteride was available from 3 retrospective cohort studies, indicating that dutasteride may be more effective in reducing the episodes of AUR (Odds ratioϭ0.79; 95%CIϭ0.68-0.93; pϭ0.0042) and the NfS (Odds ratioϭ0.77; 95%CIϭ0.61-0.98; pϭ0.03) relative to finasteride. CONCLUSIONS: The current evidence on the efficacy of dutasteride and finasteride makes an indirect comparison between the two 5-ARIs difficult; however, data retrieved from observational studies indicate improved clinical performance of dutasteride compared to finasteride.
PIH6 ANTIPSYCHOTIC USE AND RISK OF NURSING HOME ADMISSION AMONG COMMUNITY-DWELLING DUAL ELIGIBLE BENEFICIARIES
Aparasu RR, Chatterjee S University of Houston, Houston, TX, USA OBJECTIVES: Antipsychotic agents are often used for behavioral symptoms of dementia and psychoses. This study evaluated the risk of nursing home admission associated with use of antipsychotics among community-dwelling (Medicare and Medicaid) dual eligible beneficiaries in the United States. METHODS: The study involved a retrospective cohort design matched on propensity score using Medicare and Medicaid Analytical eXtract (MAX) data from four US states. The study population included all elderly dual eligible community dwelling beneficiaries (aged Ͼ 65 years) who initiated antipsychotics anytime during July 1, 2001 and December 31, 2003. Antipsychotic users were followed till the occurrence of nursing home admission or, end of the study period, whichever occurred earlier. The risk of nursing home admission was modeled using Cox proportional model and extended Cox hazard model stratified on matched pairs based on propensity score, using typical agents as the reference category. RESULTS: Analysis of MedicaidMedicare community dwelling dual eligible data revealed that there were 88,989 antipsychotic users (47,090 atypical and 41, 919 typical users) in the unmatched cohort and 60,840 users in the matched cohort (30,420 atypical and 30, 420 typical users). The unadjusted rate of nursing home admission was 20.58% (6, 260) that, the risk of nursing home admission was higher among atypical users compared to typical users. CONCLUSIONS: The higher risk of nursing home admission among atypical users compared to typical users may be attributable to indication bias. Since atypical antipsychotics are often used to control behavioral symptoms of dementia, it is possible that patients with behavioral symptoms treated with atypical agents were subsequently admitted to nursing homes.
PIH7 RISK OF ALL-CAUSE HOSPITALIZATION IN DUAL ELIGIBLE BENEFICIARIES USING ANTIPSYCHOTIC AGENTS
Aparasu RR, Chatterjee S University of Houston, Houston, TX, USA OBJECTIVES: Previous studies have reported differential safety and efficacy profiles of typical and atypical antipsychotics in the elderly. The study compared the risk of all-cause hospitalization among elderly dual eligible beneficiaries (Medicare and Medicaid) using typical and atypical antipsychotic agents. METHODS: A retrospective cohort study design matched on propensity score was used to examine the risk of all-cause hospitalization among dual eligible beneficiaries 65 years or older using antipsychotic agents. The study involved use of Medicare and Medicaid Analytical eXtract (MAX) data from four US states. New antipsychotic users were followed for up to six months without any censoring. The risk of hospitalization was modeled using Cox proportional model and extended Cox hazard model stratified on matched pairs based on propensity score. RESULTS: Analysis of Medicaid-Medicare dual eligible data revealed that, there were 1, 43, 617 new antipsychotic (91, 665 atypical and 51, 952 typical) users in the unmatched cohort and 84, 162 (42,081 atypical and 42,081 typical) users in the matched cohort. The unadjusted rates of hospitalization were 27.17% and 27.96% among atypical and typical users respectively. Cox hazards regression found that, users of typical antipsychotics were marginally at a higher average risk of hospitalization compared to atypical users [Hazard Ratio, (HR), 1.07; 95% Confidence Interval, (CI), 1.04-1.10]. Results of extended Cox regression suggest that, typical users had a higher risk of hospitalization than atypical users within the initial 40 days of therapy [HR, 1.26; 95% CI, 1.21-1.31]. However, the risk of hospitalization decreased with prolonged typical use [HR, 0.90; 95% CI, . CONCLUSIONS: Overall, typical antipsychotic users were more likely to experience all-cause hospitalization than atypical users possibly due to differential safety profiles of antipsychotics. More research is needed to evaluate specific reasons for the health care impact of antipsychotic use in the elderly population.
